As the country that laid down the principal laws of heredity, introduced the contact lens to the world and successfully developed the compounds on which current anti-AIDS drugs are based, the Czech Republic is an attractive location for manufacturing and contract R&D operations.
Development of the sector is supported by effective patent protection, adoption of GMP, GLP and GCP standards, relatively non-restrictive genetic engineering and the government’s support for R&D and knowledge transfer between the science and business communities.
The Czech government set development of new pharmaceutical treatments and diagnostics as one of the top priority areas and allocated public funding of over EUR 2.5 billion in the last decade to strengthen the sector’s research infrastructure. New state-of-the-art research facilities have been completed in Prague, Brno, Olomouc and Plzeň to complement the existing institutes of the Czech Academy of Sciences and universities.
Czech research teams are internationally recognized for their quality research in molecular genetics, immunology, analytical and pharmaceutical chemistry and biochemistry, cardiology, neurology, metabolic diseases and, more recently, medical applications of nanotechnologies.
The success of companies and research institutes operating in the Czech Republic in the life-sciences sector stems from the country’s track record in R&D and high-quality education. According to Ministry of Education statistics for 2016-2017, more than 50,000 students are enrolled in natural science study programs at universities, including Charles University in Prague, which was established in 1348 and thus ranks among the oldest universities in Europe.
Reasons to Invest:
- world-class academic community and research base with a strong commitment to partnering with industry
- strong presence of large international pharmaceutical companies participating in research programs and conducting manufacturing operations
- clinical and translational research supported by close ties between universities, research institutions, industry and the public healthcare system
- availability of university graduates and industry-specific staff at competitive prices
- regulatory and patent environment in harmony with that of the EU
- supportive business environment and incentives for both R&D and manufacturing
Source: CzechInvest, 2017